Terrapinzflyer

Flying Star and Red Dragon pills - piperazines

"FLYING STAR" AND "RED DRAGON" TABLETS (CONTAINING BENZYLPIPERAZINE (BZP) AND TRIFLUOROMETHYLPHENYLPIPERAZINE (TFMPP)) IN COMMERCIAL-STYLE PACKAGING IN SINGAPORE The DEA Special Testing and Research Laboratory (Dulles, Virginia) recently received two apparently commercially produced packages, labelled as “Flying Star” and “Red Dragon,” each containing tablets and labelled as being natural supplements (see Photos 3 and 4). The packages were obtained in Singapore by Indonesian authorities (no further details), and were submitted as an unknown/possible drug substance. The “Flying Star” package contained one white tablet (net mass 0.56 grams), while the “Red Dragon” package contained three red tablets (total net mass 1.6 grams). The tablets were about the same diameter but were about 50 percent thicker than typical Ecstasy tablets. The packaging claimed that the products would boost energy for six to eight hours, and the “Red Dragon” package also claimed that the tablets would provide an “e-sensory experience.” The ingredients listed on both packages were identical, and included: Vitamin C, “amino acids,” and “cayenne pepper piperazine blend.” Analysis of the exhibits by NMR and GC/MS, however, found none of the listed ingredients but rather a mixture of N-benzylpiperazine (BZP; 155 milligrams/tablet in “Flying Star” and 68 milligrams/tablet in “Red Dragon”) and 1-(3-trifluoromethylphenyl)piperazine (TFMPP; not quantitated) in both exhibits. No other active compounds were found in either exhibit. The Special Testing and Research Laboratory has received submissions of BZP on three occasions over the past five years; however, these are the first submissions of BZP tablets in commercial-type packaging to the laboratory.  

Flying Star and Red Dragon pills - piperazines
Terrapinzflyer, Sep 17, 2009
Tags:
    There are no comments to display.
  • Category:
    Piperazines
    Uploaded By:
    Terrapinzflyer
    Date:
    Sep 17, 2009
    View Count:
    387
    Comment Count:
    0